Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trialBradley J. Monk, Jyoti Mayadev, Takafumi Toita et al.|The Lancet Oncology|2023Cited by 214
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian CancerNing Li, Lingying Wu, Lin An et al.|JAMA Oncology|2023Cited by 165
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trialsBradley J. Monk, Antonio González-Martı́n, Takayuki Enomoto et al.|Cancer Treatment Reviews|2022Cited by 135
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Linjuan Zeng, Jihong Liu et al.|Nature Medicine|2024Cited by 41
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket studyLingfang Xia, Xiaohua Wu, Jin Peng et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 39